Gilead Sciences: Rating Upgrade Warranted On HIV Division Strength

Gilead Sciences, Inc. is rated a Buy with robust profitability, solid dividend, prudent M&A and 15-20% upside potential. Read ...
Business Wire

Merck Announces Positive Topline Results from the Pivotal Phase 3 Trial Evaluating Investigational, Once-Daily, Oral, Two-Drug, Single-Tablet Regimen of Doravirine/Isl…

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced topline results from the pivotal ...
Zacks Investment Research on MSN

MRK HIV Regimen Meets Goal in New Study, Gains EU Nod for Keytruda SC

Merck MRK announced positive top-line results from a pivotal late-stage study evaluating its investigational, once-daily, ...
Clinical Trials Arena on MSN

MSD’s once-daily HIV pill non-inferior to Biktarvy in Phase III trial

MSD announced the data just days after Gilead also touted success with a once-daily antiretroviral therapy (ART).